KAPA 10-Q: SEC filing
Kairos Pharma, LTD.
Filed with the SEC on · accession 0001493152-26-051822
KAPA filed a 10-Q (quarterly report) with the SEC on Nov 13, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -5.6% by the first close after the filing.
Summary of the filing
Kairos Pharma, LTD. filed its quarterly report on Form 10-Q for the period ending September 30, 2026, reporting financial results and ongoing clinical development activities.
Key details
How KAPA stock reacted
Close before
$0.48
Nov 12, 2026
First close after
-5.62%
$0.45
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for KAPA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for KAPA?
Click hereFrequently asked questions
What did KAPA file with the SEC on Nov 13, 2026?
KAPA filed a 10-Q (SEC filing). Kairos Pharma, LTD. filed its quarterly report on Form 10-Q for the period ending September 30, 2026, reporting financial results and ongoing clinical development activities.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did KAPA stock react to this filing?
KAPA closed at $0.48 before the filing and $0.45 on Nov 13, 2026 (-5.62%).
Other KAPA SEC filings
Get alerts when KAPA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days